CUT STACK (150 MG/ML – 10 ML) – Hilma Biocare

Cut Stack Strength: 150 mg/ml. Molecular Formula: C17H19N5 Molecular Weight: 322.1023 g/mol Active Ingredients: Trenbolone Acetate 50 mg, Testosterone Propionate 50 mg, Drostanolone Propionate 50 mg CAS number: 434-22-0 Dosage Form: Injectable, oil base sterile solution Route: Injection Market Status: Prescription Company: Hilma Biocare DESCRIPTION Cut Stack is an injectable steroid that contains ob is testosterone propionate, trenbolone acetate and drostanolone propionate. Testosterone propionate is designed to reach peak testosterone serum levels within 24 hours of IM administration and remain elevated for 2 to 3 days. Testosterone propionate is suitable for the treatment of hypogonadism and other disorders related to androgen deficiency. Testosterone Propionate has both anabolic and androgenic effects. Testosterone supplementation has been demonstrated to increase strength and growth of new muscle tissue, frequently with increases in libido. Trenbolone Acetate is an anabolic steroid with significant anabolic and androgenic effects. The fast oto acting ester produces a rapid increase in serum trenbolone levels which remain elevated for several days thereafter. inon Trenbolone promotes significant increases in strength, muscle anabolism, appetite, and aggression; and has been demonstrated to reduce body fat. Drostanolone Propionate is a synthetic derivative of dihydrotestosterone, producing an anabolic effect and promoting protein synthesis as well as creating positive nitrogen balance in humans. Since it is a derivative of dihydro- testosterone, drostanolone does not aromatize to estrogens. Drostanolone Propionate have significant anabolic and androgenic properties promoting an increase in strength and growth of muscle tissue while acting as an estrogen antagonist. The combination of a short-acting propionate ester with a long- acting enanthate ester produces rapid increases in serum drostanolone levels with a sustained duration of 5- 8 days. ADVERSE REACTIONS Male: Gynecomastia, s excessive frequency and duration of penile erections, oligospermia. Skin and Appendages: Hirsutism, male pattern baldness and acne, gynecomastia. Fluid/electrolyte Disturbances:Retention of sodium, chloride, water, potassium, calcium, and inorganic phosphates. Gastrointestinal: Nausea, cholestatic jaundice, alterations in liver function tests; rarely, hepatocellular neoplasms, peliosis hepatitis, hepatic adenomas, and cholestatic hepatitis. Hematologic: Suppression of clotting factors II, V, VII, & X; bleeding in patients on anticoagulant therapy. Nervous System: Increased or decreased libido, head- ache, anxiety, depression, and generalized paresthesia. Other: Serum lipid changes, hypercalcaemia, hypertension, oedema, priapism, and potentiation of sleep apnea. CONTRAINDICATIONS Patients with known hypersensitivity to any ingredients in this product. Patients with known or suspected carcinomas of the breast, testis, or prostate. Patients with severe heart disease, liver disease of kidney disease or with a history of epilepsy. Products containing testosterone should not be used in women as they may cause virilization and fetal harm. PRECAUTIONS Because androgens may alter serum cholesterol concentra- tion, caution should be used when administering these drugs to patients with a history of myocardial infarction or coronary artery disease. Patients on oral anticoagulant therapy require close monitoring especially when androgens are started or stopped. Diabetics: androgens may alter the metabolism of oral hypoglycemic agents or may change insulin sensitivity in patients with diabetes mellitus which may require adjustment of dosage of insulin and other hypoglycemic drugs. PATIENT MONITORING Serum Cholesterol, HDL, LDL, TG. Hemoglobin and Hematocrit, Hepatic function tests – AST/ALT Prostatic specific antigen- PSA, Testosterone: total, free. and bioavailable. Dihydrotestosterone & Estradiol Male patients over 40 should undergo a digital rectal examination and evaluate PSA prior to androgen use. Periodic evaluations of the prostate should continue while on androgen therapy, especially in patients with difficulty in urination or with changes in voiding habits. DOSAGE AND ADMINISTRATION Daily dosage for males is from 150-450 mg. The drug is not recommended for women. PRESENTATION Cut Stack 150 mg/ml, 10 ml multiple dose vial. STORAGE Store in a cool dry place between 15 – 25°C. Protec More you can find on our website: hilmabioshop.com/shop